Denosumab ameliorates muscle indices in Chinese osteoporosis patients through clinical and bioinformatic evidence of RANKL in sarcopenia
Year: 2025
Type: article
Abstract: = 0.007) and enriched in PI3K-Akt, MAPK, and cytoskeletal signaling pathways related to muscle growth and inflammation. These findings indicate that denosumab not only enhances bone mass but also improves muscle strength and function, potentially through RANKL inhibition and modulation of myogenic and inflammatory pathways, supporting its therapeutic potential for patients with coexisting osteoporosis and sarcopenia.
Source: iScience
Authors: Shaotian Li, Shanshan Hu, Xiaoli Zheng, Xiong Ku, Jingfeng Zou, Andong Zhang, Guqiao Nie, Yiting Liu, Chunhui Tian, Mi Yan, Yilan Yin, Yun Liu, Jingjing Wan, Wei Tan, Wen Peng
Language: English
Subfield: Physiology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $3,240
OpenAlex ID: W4417488642